Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer
March 16 2022 - 4:05PM
Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing
a disruptive new platform for proteomics, announced today the
appointment of Scott D. Thomas as Chief Commercial Officer
effective March 21, 2022. Mr. Thomas joins Seer from Singular
Genomics, where he served as Senior Vice President, Sales and
Marketing. Prior to Singular, he spent over two decades with
increasing commercial responsibilities within the life sciences
industry, including 11 years at Illumina.
“I’m thrilled to welcome Scott, whose leadership and breadth of
expertise in the commercialization of life sciences tools
complements the balance of our talented executive team,” said Omid
Farokhzad, Chief Executive Officer and Chair of Seer. “As we
accelerate our commercial efforts following the broad release of
our Proteograph Product Suite, we’re excited to have Scott lead the
expansion and building of our global commercial organization, and
to leverage his extensive knowledge of markets around the world to
reach and empower a broad range of customers to achieve exceptional
outcomes.”
Prior to joining Singular Genomics, where he led the
go-to-market strategy for the company’s next generation benchtop
sequencer, consumables, and service products, Mr. Thomas served
numerous roles with escalating commercial responsibilities at
Illumina, most recently as Vice President, Global Commercial
Strategy and Enablement. Previously he served as Vice President and
General Manager of Illumina Japan, and Senior Director, Sales for
Europe, Middle East and Africa. Before his tenure at Illumina, Mr.
Thomas held roles for Providence Health and Services, Roche, and
Abbott Laboratories.
“We’re at a pivotal time in the proteomics field, where
unconstrained access to deep unbiased content can unlock biology;
open entirely new markets and expand existing markets in ways
previously not possible,” said Mr. Thomas. “The Proteograph Product
Suite is uniquely able to provide deep access to the proteome at
scale and drive the next wave of breakthrough scientific
discoveries. I couldn’t be joining the Seer team at a more exciting
time in the company’s journey,”
About Seer
Seer™ is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, that reflect the Company’s current views with
respect to certain current and future events and performance. Such
forward-looking statements are based on the Company’s beliefs and
assumptions and on information currently available to it at the
time of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause the Company’s actual results, performance or achievements to
be materially different from those expressed or implied by the
forward-looking statements, including but not limited to statements
regarding acceleration of commercial efforts, a global commercial
organization, and a broad range of customers and outcomes. These
and other risks are described more fully in the Company’s filings
with the Securities and Exchange Commission (“SEC”), including the
Company’s Annual Report on Form 10-K for the year ended December
31, 2021, and other filings that the Company may make with the SEC
from time to time. Except to the extent required by law, the
Company undertakes no obligation to update such statements, and
specifically disclaims, any obligation to update any
forward-looking statements.
Media Inquiries: Karen Possematopr@seer.bio
Investor Inquiries: Carrie Mendivil investor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024